Git 'er done, git 'er done, I guess... My previous alias, JDavenport, was deactivated at my request yesterday. All posts have been retained, per Stockhouse policy.
It appears to me, from the recent filings on SEDAR, that if Bioasis shareholders vote this deal down then Bioasis could default on its loans and that all of its assets, including patents, existing deals and the xB3 platform, could be lost to the debt holders. I don't know, if the deal is voted down, whether it would be possible to make a deal with debt holders or to raise sufficient capital to pay the debts, and to avoid default.
There is a possibility that Bioasis shareholders may benefit from keeping their Bioasis/Biodexa shares. Selling Bioasis at 5¢ or 6¢ may be an act of anger, not of solemn consideration. I believe that forces will likely be brought to bear on the stock to push it upward. So, I would hold the stock and let it play out. Even if parts of the old Bioasis technology are sold into private hands, xB3 is big enough for everybody to make money if xB3 works as hoped.
My opinions about the potential value of xB3 remain intact, and I think there is still a lot of money on the table. I hope that you all will have a decent share of it.
Watch out for prophetoffactz. He seeks out DD that supports his current trade and he copy/pastes it. He does not have a considered opinion about anything. Buying at 5¢, as he likely has done, is a no-brainer that capitalizes on the anger of others. He will pump the deal and will then pump Biodexa stock until he has sold it and will then reverse his public opinion while he's buying back in.
He isn't doing anything here that you can't and shouldn't be doing for yourselves. My guess is that most of you are talking comfort from the fact that he is posting this stuff, rather than taking comfort from what he is posting. I doubt his stuff is being read to a very high degree.
And remember, the very people touting this deal are the very same people who are responsible for you losing over 90% of whatever potential value you might have had in Bioasis. In the end, their own inability to perform has led to a deal that they now express great pride in, and it's very unbecoming. A number of people have expressed to me their disgust at the smile on Dr. Deborah Rathjen's face in the webinar.
The people buying xB3 want it. THEY WANT IT! They are buying it with purpose and they have put a lot of time and effort into getting it done. That tells you that they place huge value on xB3, no matter how little they're paying for it. They have an interest, it appears, in the eventual success of xB3, and also, I hope, in the eventual success of Biodexa, although there is no guarantee that their values are, or will be, closely linked, not if the xB3 platform is sold off.
Midatech and Bioasis shareholders, upon closing, will own less than 24% of Biodexa (or something like that), Bioasis shareholders with just under 10% and Midatech shareholders with 13% or 14%. It means that the players in this deal consider the two companies to have very similar values. Too bad the companies are in such bad shape that they can't do a deal that leaves shareholders in better shape.
I'm watching KayakerBC's posts. He's worth watching. No BS.
Later...
JD Boomskid (JD BS, hee hee...!)